Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

Running, not enrolling · Phase 2

Conditions studied: Schizophrenia, Treatment Resistant Depression, Aging, Premature

In brief

This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.

Key facts

Study ID

NCT05838560

Run by

Washington University School of Medicine

People needed

40

Starts

2023-07-01

Expected to finish

2027-10-01

Last updated by the study team

2026-04-21

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Either major depression, which is treatment-resistant (currently depressed despite at least 2 adequate trials of antidepressants in this or the previous episode), or schizophrenia/schizoaffective disorder.
• Age 50+ (60+ for depression).
• Three conditions associated with aging (e.g., hypertension/diabetes/metabolic syndrome, cardiac disease, lung disease other than asthma, cancer with adult-onset, arthritis, and inflammatory diseases typically seen in aging).
• No history of dementia by patient report.
• Already taking an adequate dose of medication for schizophrenia/schizoaffective disorder or depression.

You may not qualify if…

• Contraindications for dasatinib or quercetin
• Active SI such that participant could not be safely managed in an outpatient clinical trial.
• Taking medications that are strong CPY3A4 inhibitors or strong inducers, or that induce senescence (e.g., alkylating agents, anthracyclines, platins/other chemotherapy), or everolimus and topotecan (which have interactions with quercetin).
• All medications and medical conditions will be reviewed by physician study investigators to determine whether the medication or condition, in the opinion of the investigators, makes the participant inappropriate for the study. Examples of such potential excluding conditions: Active inflammatory, infectious, or malignant disease; sensory deficits that would interfere with assessments; recent heart attack or stroke; severe bleeding disorder; uncontrolled hypertension or diabetes mellitus; active liver disease or cirrhosis; current use of systemic steroids, quinolone antibiotics, hydroxychloroquine or chloroquine.

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.